{"id":"0f08989ff88d","type":"article","url":"https://hartvaat.nl/2026/05/11/finearts-hf-subanalyse-virale-luchtweginfecties-triggeren-hartfalen-verslechteri/","title":"FINEARTS-HF subanalyse: virale luchtweginfecties triggeren hartfalen-verslechtering, finerenon-effect blijft behouden","title_en":"","category":"hartfalen","category_label":"Hartfalen","professions":["cardioloog","huisarts","internist"],"tags":["finearts-hf","heart-failure-2026","hfmref","hfref","step-hfpef"],"journal":"European Heart Journal","doi":"10.1093/eurheartj/ehag384","source_url":"https://doi.org/10.1093/eurheartj/ehag384","authors":["Ragnhild Helseth","Brian L. Claggett","Ankeet Bhatt","Orly Vardeny","Henri Lu","Scott D. Solomon","FINEARTS-HF Investigators"],"significance":6,"published":"2026-05-12","source_date":"2026-05-11","image":"","kennis":["https://hartvaat.nl/kennis/hartfalen/wat-is-hartfalen/","https://hartvaat.nl/kennis/hartfalen/hfpef-hartfalen-met-behouden-ejectie/"],"congress":"heart-failure-2026","summary_en":"FINEARTS-HF (n=6,001) sub-analysis on viral respiratory tract infections (RTIs): RTIs were associated with subsequent worsening HF events and excess mortality, particularly in symptomatic patients. Finerenone did not modify RTI incidence, but its benefit on the primary outcome was preserved across patients with and without intercurrent RTI. Supports vaccination policy emphasis in HFmrEF/HFpEF and reassures that finerenone benefit is robust to common viral illness.","created":"2026-07-03T10:32:55Z","updated":"2026-07-03T18:39:33Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Subanalyse van de FINEARTS-HF-trial (finerenon bij HF met mildly reduced of preserved ejectiefractie, n=6.001): incidentie, voorspellers en uitkomsten van virale luchtweginfecties (RTI's) tijdens trial-follow-up. RTI's gingen gepaard met daaropvolgende verslechterende hartfalenevents en oversterfte; de absolute event rate was hoger bij patiënten met ernstigere HF-symptomen op baseline. Finerenon modificeerde de incidentie van RTI's niet, maar het relatieve voordeel van finerenon op het primaire eindpunt bleef behouden bij patiënten met én zonder intercurrente RTI. Conclusie: luchtweginfectie is een herkenbare trigger voor hartfalen-verslechtering in HFmrEF/HFpEF — relevant voor vaccinatiebeleid (griep, COVID-19, RSV) en voor de ketenzorg bij intercurrente koorts/luchtwegklachten. Finerenon-winst is robuust voor deze frequent voorkomende klinische gebeurtenis.","abstract_original":"Sub-analysis of the FINEARTS-HF trial (finerenone in HF with mildly reduced or preserved ejection fraction, n=6001) examining the incidence, predictors and outcomes of viral respiratory tract infections (RTIs) over the trial follow-up. RTIs were associated with subsequent worsening heart failure events and excess mortality, with the absolute event rate higher in patients with more severe HF symptoms at baseline. Finerenone did not modify the rate of RTI episodes, but the relative benefit of finerenone on the primary outcome was preserved across patients with and without intercurrent RTI. The findings position respiratory infection as a recognisable trigger of HF decompensation in HFmrEF/HFpEF — relevant for vaccination policy and acute-illness pathway planning — and confirm that finerenone benefit is robust to this common clinical event."}